Pharmacyclics and Catalent Solidify Partnership on Imbruvica
Catalent Pharma Solutions, a global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, has signed an agreement with Pharmacyclics for the oncology drug IMBRUVICA (Ibrutinib). This follows a successful multiple-year development and clinical manufacturing partnership that aided Pharmacyclics’ expedited New Drug Application (NDA) submission and approval by FDA.
Under the agreement, Catalent will provide drug product capsules for both commercial supply and ongoing clinical trials. After review by FDA, IMBRUVICA received approval on 13 November 2013, for treatment of patients with mantle cell lymphoma who have received at least one prior therapy. This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established.
IMBRUVICA is a first in class, oral therapy and is a new agent that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B cells. IMBRUVICA blocks signals that tell malignant B cells to grow and divide uncontrollably. IMBRUVICA has been granted three Breakthrough Therapy Designations by FDA, intended to expedite the development and review of drugs for serious or life-threatening conditions, a first for an oncology drug. To date, seven Phase III trials have been initiated with IMBRUVICA and a total of 30 trials are currently registered on www.clinicaltrials.gov.
“It is important that we work with a development partner with expertise in both clinical and commercial supply as well as US and worldwide GMP regulations, to ensure reliable quality supply to patients,” commented Heow Tan, Chief of Technical Operations at Pharmacyclics. “Catalent’s extensive experience will help us meet the demands of the clinical and commercial supply of Ibrutinib.”
“We are delighted to see this important treatment approved and to have reached an agreement to continue our successful partnership with Pharmacyclics at our accelerated development programmes center of excellence in Kansas City,” said Christine Dolan, Vice President and General Manager of Catalent’s Development and Clinical Services business. “Our experience in the development and commercial supply of a variety of dose forms, as well as our analytical and regulatory expertise, enable Catalent to quickly bring quality products to market, faster.”
The agreement was reached after a successful FDA Pre-Approval Inspection at Catalent’s site in Kansas City, MO, that resulted in zero observations. The 450,000 sq. ft. facility provides a range of fully integrated support services, from formulation development and analytical testing, to clinical and commercial scale manufacturing and packaging of a variety oral dose forms. Its co-located end-to-end drug development solutions provide speed and flexibility to help Catalent’s customers accelerate their drug development to market.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance